Andrew Berens, M.D.
Senior Managing Director, Targeted Oncology
Andrew Berens, M.D., is a Senior Research Analyst at Leerink Partners covering Targeted Oncology.
Prior to joining the firm in 2018, Andrew was an Executive Director and Senior Biotechnology Research Analyst at Morgan Stanley focusing on mid- and small-cap biotechnology companies. He practiced as an emergency medicine physician for a decade before starting his career in equity research. He also worked in the pharma industry at Ikaria Pharmaceuticals, where he was a Senior Director in business development, leading search and development efforts.
In 2017 he was named a Runner Up in Institutional Investor’s 2017 All–America Research Team for Biotechnology/Mid- & Small-Cap.
He earned M.B.A. degrees from Columbia Business School and London Business School, his M.D. from Emory University, and an undergraduate degree in English Literature from Tulane University.